CVSI Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of -11.73% compared to CV Sciences, Inc.'s net margin of -135.28%. CV Sciences, Inc.'s return on equity of -80.15% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

CV Sciences, Inc. has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than CV Sciences, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than CV Sciences, Inc..

CV Sciences, Inc. has a beta of 0.353, which suggesting that the stock is 64.748% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

CV Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CV Sciences, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

CV Sciences, Inc. quarterly revenues are $3.3M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. CV Sciences, Inc.'s net income of -$382K is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, CV Sciences, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CV Sciences, Inc. is 0.33x versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

KalVista Pharmaceuticals, Inc. has a net margin of -11.73% compared to CV Sciences, Inc.'s net margin of -361.39%. CV Sciences, Inc.'s return on equity of -80.15% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

CV Sciences, Inc. has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 89.02%. Given that CV Sciences, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe CV Sciences, Inc. is more attractive than KalVista Pharmaceuticals, Inc..

CV Sciences, Inc. has a beta of 0.353, which suggesting that the stock is 64.748% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.

CV Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CV Sciences, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

CV Sciences, Inc. quarterly revenues are $3.3M, which are smaller than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. CV Sciences, Inc.'s net income of -$382K is higher than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, CV Sciences, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CV Sciences, Inc. is 0.33x versus 56.89x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -11.73% compared to CV Sciences, Inc.'s net margin of 15.59%. CV Sciences, Inc.'s return on equity of -80.15% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

CV Sciences, Inc. has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 17.46%. Given that CV Sciences, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe CV Sciences, Inc. is more attractive than Travere Therapeutics, Inc..

CV Sciences, Inc. has a beta of 0.353, which suggesting that the stock is 64.748% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

CV Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CV Sciences, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

CV Sciences, Inc. quarterly revenues are $3.3M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. CV Sciences, Inc.'s net income of -$382K is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, CV Sciences, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CV Sciences, Inc. is 0.33x versus 7.36x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenetic Biosciences, Inc. has a net margin of -11.73% compared to CV Sciences, Inc.'s net margin of -49.65%. CV Sciences, Inc.'s return on equity of -80.15% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.

CV Sciences, Inc. has a consensus price target of --, signalling upside risk potential of 92.31%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1474.8%. Given that Xenetic Biosciences, Inc. has higher upside potential than CV Sciences, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than CV Sciences, Inc..

CV Sciences, Inc. has a beta of 0.353, which suggesting that the stock is 64.748% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.

CV Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CV Sciences, Inc. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.

CV Sciences, Inc. quarterly revenues are $3.3M, which are larger than Xenetic Biosciences, Inc. quarterly revenues of $1M. CV Sciences, Inc.'s net income of -$382K is higher than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, CV Sciences, Inc.'s price-to-earnings ratio is -- while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CV Sciences, Inc. is 0.33x versus 1.37x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.